ATOSSA THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATE MENTS OF CASH FLOWS
(in thousands)
| For the Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(34,770) | $(25,504) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation | 2,646 | 2,292 |
| Impairment charge on investment in equity securities | — | 1,710 |
| Depreciation | 16 | 17 |
| Loss on disposal of assets | — | 7 |
| Changes in operating assets and liabilities: | ||
| Prepaid materials | (983) | (611) |
| Prepaid expenses and other current assets | 37 | 997 |
| Other assets | 4 | 331 |
| Accounts payable | 3,614 | (127) |
| Accrued expenses | 388 | (54) |
| Payroll liabilities | (304) | 208 |
| Other current liabilities | (410) | (296) |
| Net cash used in operating activities | (29,762) | (21,030) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchase of property and equipment | (23) | (19) |
| Net cash used in investing activities | (23) | (19) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from exercise of warrants | — | 3,673 |
| Net cash provided by financing activities | — | 3,673 |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (29,785) | (17,376) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE | 71,194 | 88,570 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE | $41,409 | $71,194 |
| RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | ||
| Cash and cash equivalents | 41,299 | 71,084 |
| Restricted cash | 110 | 110 |
| Total cash, cash equivalents and restricted cash | $41,409 | $71,194 |
| NON-CASH INVESTING AND FINANCING ACTIVITIES | ||
| Common stock issued upon cashless exercise of stock options | $— | $273 |
| Conversion of Series B convertible preferred stock to common stock | $5 | $— |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.